Bausch + Lomb BLCO Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Business | ||||||
| Pharmaceuticals | $266M+19.8% | $319M+19.0% | $280M+13.4% | $260M+6.1% | $222M+6.2% | |
| Surgical | $228M+6.5% | $249M+7.8% | $215M+4.4% | $216M+3.3% | $214M+8.6% | |
| Vision Care | $711M+8.4% | $778M+7.6% | $736M+7.6% | $753M+8.0% | $656M+3.3% | |
| Operating Income (Loss) by Business | ||||||
| Pharmaceuticals | $66M+500% | $134M+139% | $76M+10.1% | $37M-52.6% | $11M-79.2% | |
| Surgical | $9M+229% | $15M-6.3% | $8M-38.5% | $2M-50.0% | -$7M-164% | |
| Vision Care | $202M+14.8% | $247M+4.2% | $217M+8.0% | $209M+8.9% | $176M-1.1% | |
| Selling, general and administrative (Note 4) by Business | ||||||
| Pharmaceuticals | $138M-9.8% | $133M-15.8% | $132M-3.6% | $154M+22.2% | $153M+25.4% | |
| Surgical | $73M0.0% | $80M+14.3% | $72M+12.5% | $73M+9.0% | $73M+14.1% | |
| Vision Care | $228M+3.2% | $223M+7.2% | $225M+2.7% | $243M+3.0% | $221M+0.9% | |
| R&D by Business | ||||||
| Pharmaceuticals | $22M+144% | $17M+54.5% | $15M+114% | $12M+33.3% | $9M+50.0% | |
| Surgical | $13M+18.2% | $9M-30.8% | $11M+10.0% | $12M+20.0% | $11M+22.2% | |
| Vision Care | $10M+25.0% | $14M+40.0% | $15M+25.0% | $11M0.0% | $8M-38.5% | |
| Goodwill, Foreign Currency Translation, Gain (Loss) by Business | ||||||
| Pharmaceuticals | $13M+139% | -$1M-102% | $0+100% | -$71M-1,520% | -$33M-283% | |
| Surgical | $3M+160% | -$1M-114% | $0+100% | -$7M— | -$5M-350% | |
| Vision Care | $5M+183% | -$2M-109% | —— | -$22M-650% | -$6M-175% | |
| Goodwill by Business | ||||||
| Pharmaceuticals | $731M+8.0% | $744M+15.5% | $743M+6.1% | $748M+11.6% | $677M+0.3% | |
| Surgical | $456M+28.5% | $459M+31.1% | $361M+9.4% | $362M+11.7% | $355M+9.6% | |
| Vision Care | $3.55B+0.4% | $3.56B+0.7% | $3.55B+0.1% | $3.56B+0.4% | $3.54B-0.4% | |
| Total revenues by Product | ||||||
| Branded and Other Generics | $49M-9.3% | $71M+2.9% | $59M-15.7% | $58M-23.7% | $54M-18.2% | |
| Devices | $480M+7.1% | $518M+8.8% | $484M+6.4% | $472M+6.1% | $448M+5.7% | |
| OTC | $444M+8.6% | $490M+6.1% | $454M+8.1% | $482M+7.8% | $409M+3.5% | |
| Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues by Product | ||||||
| Other revenues | $1M0.0% | $1M-50.0% | $1M— | $2M+100% | $1M0.0% | |
| Product sales | $482M+0.2% | $532M+6.6% | $509M+9.7% | $523M+8.5% | $481M+13.7% | |
| Number of lawsuits pending by Geography | ||||||
| CA-BC | $10.0% | —— | $1— | $1— | $1— | |
| CA-QC | $10.0% | —— | $1— | $1— | $1— | |
| Canada | $20.0% | —— | $2— | $2— | $2— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bausch + Lomb break its business down?
- Bausch + Lomb (BLCO) reports total revenues by business across 3 parts — Pharmaceuticals, Surgical and Vision Care. Each is extracted from the segment footnotes and tracked over time.
- Where does Bausch + Lomb's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bausch + Lomb's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.